Arrowhead Pharmaceuticals Statistics
Arrowhead Pharmaceuticals (HDP1) Stock Statistics & Valuation Metrics
Total Valuation
Arrowhead Pharmaceuticals has a market cap or net worth of EUR 6.24B. The enterprise value is EUR 11.46B.
- Market Cap
- EUR 6.24B
- Enterprise Value
- EUR 11.46B
Share Statistics
Arrowhead Pharmaceuticals has 141,254,470 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 141,254,470
- Owned by Insiders
- 3.64%
- Owned by Institutions
- 49.70%
Financial Efficiency
Arrowhead Pharmaceuticals’s return on equity (ROE) is -0.00 and return on invested capital (ROIC) is 4.65%.
- Return on Equity (ROE)
- -0.00
- Return on Assets (ROA)
- -0.00
- Return on Invested Capital (ROIC)
- 4.65%
- Return on Capital Employed (ROCE)
- 0.08
- Revenue Per Employee
- 1.17M
- Profits Per Employee
- -2,293.952
- Employee Count
- 711
- Asset Turnover
- 0.60
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Arrowhead Pharmaceuticals is -22.04. Arrowhead Pharmaceuticals’s PEG ratio is 0.00.
- PE Ratio
- -22.04
- PS Ratio
- 10.41
- PB Ratio
- 15.20
- Price to FCF
- -92.83
- Price to Operating Cash Flow
- -119.84
- PEG Ratio
- 0.00
Income Statement
In the last 12 months, Arrowhead Pharmaceuticals had revenue of 829.45M and earned -1.63M in profits. Earnings per share was -0.01.
- Revenue
- 829.45M
- Gross Profit
- 829.45M
- Operating Income
- 98.35M
- Pretax Income
- 51.53M
- Net Income
- -1.63M
- EBITDA
- 164.82M
- Earnings Per Share (EPS)
- -0.01
Cash Flow
In the last 12 months, operating cash flow was -59.05M and capital expenditures -16.06M, giving a free cash flow of -75.11M billion.
- Operating Cash Flow
- -59.05M
- Free Cash Flow
- -75.11M
- Free Cash Flow per Share
- -0.52
Dividends & Yields
Arrowhead Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -1.08%
- Earnings Yield
- -4.54%
Stock Price Statistics
- Beta
- 0.97
- 52-Week Price Change
- 24.26%
- 50-Day Moving Average
- 59.03
- 200-Day Moving Average
- 62.09
- Relative Strength Index (RSI)
- 29.85
- Average Volume (3m)
- 298
Important Dates
Arrowhead Pharmaceuticals upcoming earnings date is Feb 10, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 12, 2026
- Next Earnings Date
- Feb 10, 2027
- Ex-Dividend Date
- ―
Financial Position
Arrowhead Pharmaceuticals as a current ratio of 4.86, with Debt / Equity ratio of 78.59%
- Current Ratio
- 4.86
- Quick Ratio
- 4.86
- Debt to Market Cap
- 0.06
- Net Debt to EBITDA
- 0.85
- Interest Coverage Ratio
- 1.10
Taxes
In the past 12 months, Arrowhead Pharmaceuticals has paid 21.42M in taxes.
- Income Tax
- 21.42M
- Effective Tax Rate
- 0.42
Enterprise Valuation
Arrowhead Pharmaceuticals EV to EBITDA ratio is -58.03, with an EV/FCF ratio of -103.28.
- EV to Sales
- 11.59
- EV to EBITDA
- -58.03
- EV to Free Cash Flow
- -103.28
- EV to Operating Cash Flow
- -131.36
Balance Sheet
Arrowhead Pharmaceuticals has EUR 1.60B in cash and marketable securities with EUR 864.07M in debt, giving a net cash position of EUR 737.89M billion.
- Cash & Marketable Securities
- EUR 1.60B
- Total Debt
- EUR 864.07M
- Net Cash
- EUR 737.89M
- Net Cash Per Share
- EUR 5.22
- Tangible Book Value Per Share
- EUR 3.21
Margins
Gross margin is 100.00%, with operating margin of -33.82%, and net profit margin of -47.79%.
- Gross Margin
- 100.00%
- Operating Margin
- -33.82%
- Pretax Margin
- -37.65%
- Net Profit Margin
- -47.79%
- EBITDA Margin
- -19.97%
- EBIT Margin
- -23.82%
Analyst Forecast
The average price target for Arrowhead Pharmaceuticals is EUR 97.06, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- EUR 97.06
- Price Target Upside
- 119.34% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 12
- Revenue Growth Forecast
- 5.82%
- EPS Growth Forecast
- -88.01%
Scores
- Smart Score
- 1
- AI Score
- ―
